Replies to post #23517 on Humanigen Inc (fka HGENQ)

[Knuckle Sandwich]

The total number of study patients seems like a large at 2,282 / 4 Arms = 570 per Arm. It is a Phase III study, and I assume it will be more weighted with a larger number of patients on the front end with Prophylaxis patients. The confidence in allowing Lenzilumab to be the only choice for Severe in such a High Risk Patient I see as huge endorsement of what they believe Lenz is capable of. Australia is very familiar with Lenzilumab as it started there and there are certain benefits from Australian Government.

Bob Atwill, Head of Asia-Pacific Region at Humanigen said, “Humanigen’s expansion strategy in COVID-19 includes conducting regional clinical trials, local manufacturing, partnering and potential early market entry. Some of these opportunities may allow Humanigen Australia Pty Ltd to benefit from certain financial and tax incentives offered by the Australian government, including a potential 43.5% rebate on eligible research and development expenditures. This is a critical moment for important advancements in biotechnology and healthcare, and I look forward to progressing lenzilumab and the rest of the Company’s pipeline in the Asia-Pacific region as we grow Humanigen Australia Pty Ltd.”

https://www.businesswireindia.com/humanigen-australia-proprietary-limited-established-to-facilitate-asia-pacific-growth-plans-70514.html